These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27748523)

  • 21. Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
    Terpos E
    Leuk Res; 2008 Nov; 32(11):1646-7. PubMed ID: 18614229
    [No Abstract]   [Full Text] [Related]  

  • 22. Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
    Fujii S; Nakamura S; Oda A; Miki H; Tenshin H; Teramachi J; Hiasa M; Bat-Erdene A; Maeda Y; Oura M; Takahashi M; Iwasa M; Endo I; Yoshida S; Aihara KI; Kurahashi K; Harada T; Kagawa K; Nakao M; Sano S; Abe M
    Br J Haematol; 2018 Jan; 180(2):246-258. PubMed ID: 29327347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.
    Hiasa M; Teramachi J; Oda A; Amachi R; Harada T; Nakamura S; Miki H; Fujii S; Kagawa K; Watanabe K; Endo I; Kuroda Y; Yoneda T; Tsuji D; Nakao M; Tanaka E; Hamada K; Sano S; Itoh K; Matsumoto T; Abe M
    Leukemia; 2015 Jan; 29(1):207-17. PubMed ID: 24787487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
    Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
    Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
    Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
    Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloma bone disease.
    Sezer O
    Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
    Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
    Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.
    Bolzoni M; Donofrio G; Storti P; Guasco D; Toscani D; Lazzaretti M; Bonomini S; Agnelli L; Capocefalo A; Dalla Palma B; Neri A; Nicolini F; Lisignoli G; Russo F; Colla S; Aversa F; Giuliani N
    Leukemia; 2013 Feb; 27(2):451-63. PubMed ID: 22781592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
    Heusschen R; Muller J; Binsfeld M; Marty C; Plougonven E; Dubois S; Mahli N; Moermans K; Carmeliet G; Léonard A; Baron F; Beguin Y; Menu E; Cohen-Solal M; Caers J
    Oncotarget; 2016 May; 7(21):30712-29. PubMed ID: 27095574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanisms, current management and next generation therapy in myeloma bone disease.
    Heusschen R; Muller J; Duray E; Withofs N; Bolomsky A; Baron F; Beguin Y; Menu E; Ludwig H; Caers J
    Leuk Lymphoma; 2018 Jan; 59(1):14-28. PubMed ID: 28573897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.
    Kim JY; Cheon YH; Kwak SC; Baek JM; Yoon KH; Lee MS; Oh J
    J Bone Miner Res; 2014 Jul; 29(7):1541-53. PubMed ID: 25832436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis.
    Hsieh TP; Sheu SY; Sun JS; Chen MH
    Phytomedicine; 2011 Jan; 18(2-3):176-85. PubMed ID: 20554188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts.
    Kim JL; Kang SW; Kang MK; Gong JH; Lee ES; Han SJ; Kang YH
    J Cell Biochem; 2012 Jan; 113(1):247-59. PubMed ID: 21898547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss.
    Ruocco MG; Maeda S; Park JM; Lawrence T; Hsu LC; Cao Y; Schett G; Wagner EF; Karin M
    J Exp Med; 2005 May; 201(10):1677-87. PubMed ID: 15897281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Link between osteoclastogenesis, angiogenesis and myeloma expansion].
    Abe M
    Clin Calcium; 2008 Apr; 18(4):473-9. PubMed ID: 18379029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Artesunate inhibits RANKL-induced osteoclastogenesis and bone resorption in vitro and prevents LPS-induced bone loss in vivo.
    Wei CM; Liu Q; Song FM; Lin XX; Su YJ; Xu J; Huang L; Zong SH; Zhao JM
    J Cell Physiol; 2018 Jan; 233(1):476-485. PubMed ID: 28294321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mammalian lectin galectin-8 induces RANKL expression, osteoclastogenesis, and bone mass reduction in mice.
    Vinik Y; Shatz-Azoulay H; Vivanti A; Hever N; Levy Y; Karmona R; Brumfeld V; Baraghithy S; Attar-Lamdar M; Boura-Halfon S; Bab I; Zick Y
    Elife; 2015 May; 4():e05914. PubMed ID: 25955862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.